Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.57 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.55 |
| ▸ | YTHDC1 | Q96MU7 | 5/20 | 0.48 |
| ▸ | CDK1 | P06493 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 3/20 | 0.47 |
| ▸ | PDE4A | P27815 | 2/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.46 |
| ▸ | PDE8A | O60658 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6482227 | 0.82 | MAPK14 (0.60) | MAPK14ADORA2ACDK1PDE4APDE4B | |
| SCHEMBL6249030 | 0.81 | MAPK14 (0.53) | MAPK14ADORA2AADORA3 | |
| SCHEMBL6247857 | 0.80 | TLR9 (0.57) | MAPK14ADORA2A | |
| SCHEMBL6493063 | 0.79 | MAPK14 (0.39) | MAPK14ADORA2ACDK1PDE4APDE4B | |
| SCHEMBL6249806 | 0.75 | MAPK14 (0.56) | MAPK14YTHDC1CDK1 | |
| SCHEMBL6484946 | 0.73 | MAPK14 (0.56) | MAPK14 | |
| SCHEMBL6482024 | 0.73 | MAPK14 (1.00) | MAPK14PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6252502 | 0.71 | MAPK14 (0.53) | MAPK14ADORA2ACDK1ADORA3PDE4A | |
| SCHEMBL6247904 | 0.70 | MAPK14 (0.56) | MAPK14 | |
| SCHEMBL7536448 | 0.69 | YTHDC1 (0.74) | ADORA2AYTHDC1CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288503-A1 | Novel compounds | ADAMS JERRY L | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288503-A1 | Novel compounds | CREBBP, NCBP1, MAPKAPK2 | MAPK14 48/4885ADORA2A 4021/4885YTHDC1 4038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.